SPRYCEL
Total Payments
$165.2M
Transactions
7,964
Doctors
2,835
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $7.9M | 122 | 58 |
| 2023 | $7.8M | 158 | 82 |
| 2022 | $25.2M | 255 | 194 |
| 2021 | $19.9M | 68 | 22 |
| 2020 | $27.3M | 178 | 38 |
| 2019 | $31.7M | 1,153 | 659 |
| 2018 | $23.8M | 4,237 | 1,916 |
| 2017 | $21.6M | 1,793 | 873 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $164.7M | 995 | 99.7% |
| Consulting Fee | $245,942 | 59 | 0.1% |
| Food and Beverage | $99,773 | 6,629 | 0.1% |
| Education | $78,309 | 181 | 0.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $53,093 | 17 | 0.0% |
| Travel and Lodging | $36,011 | 77 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $8,750 | 6 | 0.0% |
Payments by Type
Research
$164.7M
995 transactions
General
$521,878
6,969 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Dasatinib-Therapy of Early Chronic Phase of CML-NONBMSSP | E.R. Squibb & Sons, L.L.C. | $40.6M | 0 |
| Therapy of Early Chronic Phase Chronic Myeloid Leukemia CML with Dasatinib and Venetoclax | E.R. Squibb & Sons, L.L.C. | $28.9M | 0 |
| Therapy of Early Chronic Phase Chronic Myeloid Leukemia (CML) with Dasatinib and Venetoclax | E.R. Squibb & Sons, L.L.C. | $25.6M | 0 |
| Dasatinib Therapy of Early Chronic Phase of CML NONBMSSP | E.R. Squibb & Sons, L.L.C. | $18.2M | 0 |
| 2016 S 0054 Early chronic CML | E.R. Squibb & Sons, L.L.C. | $14.2M | 0 |
| 2016-S-0054 Early chronic CML | E.R. Squibb & Sons, L.L.C. | $12.9M | 0 |
| Ph II Trial Dasatinib in NSCLC | E.R. Squibb & Sons, L.L.C. | $4.1M | 0 |
| Dasatinib-Hyper-CVAD Dasatinib Combo Study-NONBMSSP | E.R. Squibb & Sons, L.L.C. | $2.5M | 0 |
| PHASE I II DASA AND DECITABINE USED IN COMBO FOR PTS WITH ACCEL OR BLASTIC PHASE CML | E.R. Squibb & Sons, L.L.C. | $1.9M | 0 |
| Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States | E.R. Squibb & Sons, L.L.C. | $1.6M | 0 |
| 2016 S 0056 St Jude Total XVII | E.R. Squibb & Sons, L.L.C. | $1.5M | 0 |
| 2016-S-0056 St. Jude Total XVII | E.R. Squibb & Sons, L.L.C. | $987,212 | 0 |
| Ph II ST adjuv thera and biomkr stud with target agents in women with estro recept breast cancer | E.R. Squibb & Sons, L.L.C. | $871,218 | 0 |
| Dasatinib Hyper CVAD Dasatinib Combo Study NONBMSSP | E.R. Squibb & Sons, L.L.C. | $716,409 | 0 |
| Dasatinib-Hyper-CVAD + Dasatinib Combo Study-NONBMSSP | E.R. Squibb & Sons, L.L.C. | $685,981 | 0 |
| ISRPh II FOLFOX and dasa in adv metas pancreatic adenocarcinoma | E.R. Squibb & Sons, L.L.C. | $685,818 | 0 |
| Phase II Pediatric Ph ALL | E.R. Squibb & Sons, L.L.C. | $683,059 | 0 |
| PH II dasa KIT-pos pts with unresect local adv or stage IV mucosal, acral, or vulvovaginal melanoma | E.R. Squibb & Sons, L.L.C. | $675,860 | 0 |
| Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE | E.R. Squibb & Sons, L.L.C. | $636,991 | 0 |
| Phase I Rand Ph II Dasa or Placebo Comb with Std Chemo Radiotherapy for Newly Diagnosed GBM | E.R. Squibb & Sons, L.L.C. | $515,814 | 0 |
Top Doctors Receiving Payments for SPRYCEL
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Linda May | — | Richmond, VA | $164.7M | 1,000 |
| , M.D | Hematology & Oncology | Houston, TX | $145,224 | 35 |
| , M.D | Hematology & Oncology | Wexford, PA | $39,131 | 46 |
| , MD | Hematology | New York, NY | $29,998 | 15 |
| , M.D | Hematology & Oncology | Houston, TX | $21,971 | 9 |
| , M.D | Hematology | Indianapolis, IN | $15,745 | 11 |
| , MD | Internal Medicine | Ann Arbor, MI | $15,565 | 12 |
| , MD | Hematology & Oncology | Milwaukee, WI | $12,804 | 5 |
| , MD | Internal Medicine | Tampa, FL | $8,694 | 8 |
| , MD, MA | Medical Oncology | Durham, NC | $8,676 | 3 |
| , M.D | Hematology & Oncology | Tampa, FL | $6,224 | 4 |
| , MD | Internal Medicine | Nashville, TN | $4,905 | 2 |
| , MD | Hematology & Oncology | Augusta, GA | $4,330 | 8 |
| , MD,PHD, MRCP, | Hematology & Oncology | Ocala, FL | $4,247 | 6 |
| , M.D | Medical Oncology | Asheville, NC | $4,169 | 12 |
| , M.D | Hematology & Oncology | Goodyear, AZ | $4,153 | 3 |
| , MD | Hematology & Oncology | New York, NY | $4,000 | 1 |
| , MD | Cytopathology | Rochester, NY | $3,966 | 1 |
| , MD | Anatomic Pathology | Rochester, NY | $3,966 | 1 |
| , MD | Internal Medicine | New York, NY | $3,966 | 1 |
| , M.D | Hematology & Oncology | Cleveland, OH | $3,966 | 1 |
| , M.D.,PH.D | Hematology & Oncology | Boston, MA | $3,914 | 8 |
| , MD | Hematology & Oncology | New York, NY | $3,601 | 4 |
| , MD | Pediatrics | Atlanta, GA | $3,562 | 2 |
| , M.D | Hematology | Washington, DC | $3,493 | 11 |
Ad
Manufacturing Companies
- E.R. Squibb & Sons, L.L.C. $165.2M
- Otsuka America Pharmaceutical, Inc. $31,970
- Celgene Corporation $3,454
Product Information
- Type Drug
- Total Payments $165.2M
- Total Doctors 2,835
- Transactions 7,964
About SPRYCEL
SPRYCEL is a drug associated with $165.2M in payments to 2,835 healthcare providers, recorded across 7,964 transactions in the CMS Open Payments database. The primary manufacturer is E.R. Squibb & Sons, L.L.C..
Payment data is available from 2017 to 2024. In 2024, $7.9M was paid across 122 transactions to 58 doctors.
The most common payment nature for SPRYCEL is "Unspecified" ($164.7M, 99.7% of total).
SPRYCEL is associated with 20 research studies, including "Dasatinib-Therapy of Early Chronic Phase of CML-NONBMSSP" ($40.6M).